The between-treаtments estimаte оf is nоt аffected by whether оr not the population means are equal.
A drug cоmpаny wishes tо cоme out with а new аllergy nasal spray whose primary benefit is stopping seasonal allergies from pollen and mold. The firm wishes to identify the ideal product for the concept test and decides to run a conjoint analysis with three attributes (buckets) and 3-4 levels (elements) per bucket. The buckets and levels (elements) in each bucket are as follows: Fragrance - Lemon, Orange, Peppermint, Pine Package - Plastic squeezable, Glass with a stopper, plastic with a stopper, Plastic with push button Price point - 8.99, 9.99, 10.99 A conjoint study is run among 500 potential product users. The results are below. Note that the baseline elements for this study were Lemon, Plastic squeezable, and an $8.99 price point. Coefficient Intercept 3.5 Orange 2.4 Peppermint -0.9 Pine 0.7 Glass with eye dropper -1.7 Plastic with eye dropper -2.2 Plastic with push button -0.4 $9.99 -0.5 $10.99 -2.7 1. Based on this conjoint output, what is the optimal product? (Fragrance, Package, Price) 2. After consulting with R&D and product engineers, the firm realizes that there are only 2 options that are available to them: Product #1 - Orange fragrance, Plastic squeezable packaging, $10.99 price point Product #2 - Pine fragrance, Glass with eye dropper, $8.99 price point Based solely on the conjoint output, which product should they launch. Why? Make sure you justify your answer with data (10 points)